ArticleJournal of cosmetic dermatology2026
Dual-Targeting Oligopeptide-215 Regulates Skin Barrier Homeostasis Through Concurrent Modulation of JAK-STAT and NF-κB Signaling.
Article in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate Oligopeptide-215, a biomimetic peptide engineered from amphibian skin secretions, for its dual capacity to restore skin barrier homeostasis by concurrently targeting physical barrier proteins and inflammatory pathways via JAK-STAT and NF-κB modulation.
methodsIn vitro models used UVB-damaged HaCaT keratinocytes, LPS-stimulated RAW264.7 macrophages, and IL-4/IL-13-stimulated HaCaT cells. Assays included cell viability (MTT), migration (scratch), adhesion, barrier proteins (FLG/LOR; ELISA/IF), signaling phosphoproteins (pJAK1/pTYK2/pSTAT3/pSTAT6/pNF-κB; IF), and inflammatory mediators (NO/PGE₂/TNF-α/IL-6/IL-1β; ELISA).
resultsOligopeptide-215 antagonizes IL-13/IL-4-mediated JAK-STAT6/STAT3 signaling, thereby restoring expression of critical barrier proteins FLG and LOR. Additionally, it suppresses inflammatory responses by inhibiting NF-κB-dependent cytokine production. In UVB-damaged keratinocytes, Oligopeptide-215 promotes cellular repair through enhanced proliferation, adhesion, and migration.
conclusionThese findings revealed an innovative repairing mechanism combining physical barrier with immunologic barrier, and established Oligopeptide-215 as a potential skincare ingredient for skin barrier dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.